RobertsWLRaineyPM. Interference in immunoassay measurements of total and free phenytoin in uremic patients: A reappraisal. Clin Chem1993;39: 1872–7.
2.
RobertsWLDeBKColemanJPAnnesleyTM. Falsely increased immunoassay measurements of total and unbound phenytoin in critically ill uremic patients receiving fosphenytoin. Clin Chem1999;45: 829–37.
3.
DagerWEInciardiJFHoweTL. Estimating phenytoin concentrations by the Sheiner—Tozer method in adults with pronounced hypoalbuminemia. Ann Pharmacother1995;29: 667–70.
4.
RaineyPMRogersKERobertsWL. Metabolite and matrix interference in phenytoin immunoassays. Clin Chem1996;42: 1645–53.
5.
TozerTNWinterME. Phenytoin. In: EvansWEShentagJJJuskoWJ, eds. Applied pharmacokinetics. Principles of therapeutic drug monitoring. 3rd ed.Vancouver, WA: Applied Therapeutics, 1992:25–1–25–44.
6.
MauroLSMauroVFBachmanKAHigginsJT. Accuracy of two equations in determining normalized phenytoin concentrations. DICP1989;23: 64–8.
